Colorado-based biotech company Next Frontier Biosciences (“NFB”) today announced plans to launch a suite of purified cannabinoid products for the medical and adult-use marijuana markets in Colorado in the third quarter of 2017. NFB’s Verra Wellness line of products are scientifically formulated for accurate and consistent delivery of purified tetrahydrocannabinol (THC) and cannabidiol (CBD) in three different ratios via nasal mists and sublingual sprays. Verra Wellness will also offer a line of small batch topical salves designed to permeate skin and muscle tissue deeply without penetrating the blood stream or causing psychoactive effects.
“Next Frontier Biosciences’ Verra Wellness line of nasal, sublingual and topical products will provide cannabis patients and consumers with important alternatives to smoking, vaporizing or eating impure and poorly characterized cannabis products,” said Marc Graboyes, NFB’s co-founder and Chief Executive Officer. “We plan to launch in Colorado in the third quarter of this year and will seek to expand into the 10 legal state markets by 2020. Our team of highly experienced research scientists will also continue enhancing and expanding our product offerings by incorporating new cannabinoids and developing additional product lines with a focus on improved absorption, or bioavailability.”
“Cannabinoids are the primary active ingredients in the cannabis plant and have demonstrated a wide range of therapeutic benefits for the treatment of chronic pain, anxiety, insomnia and post-traumatic stress disorder, among other conditions,” continued Dr. Paul Johnson, Ph.D., NFB’s co-founder and Chief Scientific Officer. “At Next Frontier Biosciences, we believe that cannabinoid purification and scientific formulation are the keys to unlocking the power of the plant and developing safer and more effective cannabinoid-based products. We are reshaping the cannabis industry by designing a premium brand of trusted cannabis infused products that provide uniform composition, formulation and dosing in several discreet and highly consistent modes of administration.”
Founded in 2014, NFB has assembled a team of highly experienced biotech executives and research scientists with over 120 years of pharmaceutical drug development experience. The company employs a traditional scientific approach to product development that includes advanced purification, analytical and chemical formulation methods. NFB’s proprietary formulations were carefully developed and optimized for improved delivery via nasal, sublingual and topical administration with a focus on providing unparalleled quality, consistency and reproducibility.
“Next Frontier Biosciences is structured as an intellectual property and brand management company,” explained Mr. Graboyes. “We operate primarily through strategic collaborations with third parties who hold the licenses and approvals required to develop, manufacture and distribute our cannabis-infused products in their respective state markets. As such, we are actively seeking strategic partners to help bring our products to market in other states and countries throughout the world.”
For more information or to schedule an interview with Next Frontier Biosciences, please contact Shawna McGregor at 917-971-7852 or [email protected].
